BostonGene to present at the 2022 American Society of Clinical Oncology Annual Meeting

0

WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene today announced that three abstracts have been accepted for poster presentations and one abstract has been accepted for online publication for the 2022 ASCO Annual Meeting (ASCO), which will be held from 3 through June 7, 2022, at the McCormick Place Convention Center in Chicago, IL. BostonGene will also be exhibiting at booth 27087.

“We are excited to share our latest research at ASCO that underscores the critical need for innovative analytical tools to understand tumor and microenvironment composition and activity to improve treatment outcomes for cancer patients.” , said Nathan Fowler MD, medical director of BostonGene.

Below are details of the abstracts selected for presentation:

Abstract number: 4591

Title: A urothelial carcinoma (UC) grading system defined by genomic factors and tumor microenvironment (TME) is predictive of immunotherapeutic response

Date and time: Saturday June 4 | 1:15 p.m. – 4:15 p.m.

Location: McCormick Place Convention Center, Room A

Poster number: 82

Speaker: Krystle Nomie, PhD, BostonGene

This presentation highlights the application of the BostonGene transcriptome-based classification platform, previously reported by Bagaev et al., to identify TME subtypes for urothelial carcinoma that are predictive of response to immunotherapy.

Abstract number: 3020

Title: An AI-driven Multiplex Immunofluorescence Clinical Imaging Pipeline to Characterize Tumor Microenvironment Heterogeneity

date and time: Sunday June 5 | 8:00 a.m. – 11:00 a.m.*

Location: McCormick Place Convention Center, Room A

Poster number: 12

Speaker: Zhongmin Xiang, PhD, BostonGene

* A follow-up poster discussion highlighting the AI-driven BostonGene MxIF analytical pipeline and its automated characterization of the microenvironment across cancers will take place from 4:30-6:00 p.m. in Hall D2

This presentation highlights the importance of innovative MxIF platforms to characterize tumor heterogeneity at single-cell resolution with high accuracy in many cancers.

Abstract number: 3142

Title: A digital imaging analysis (DIA) platform for the identification of tertiary lymphoid structures (TLS) in lung adenocarcinoma (LUAD)

Date and time: Sunday June 5 | 8:00 a.m. – 11:00 a.m.

Location: McCormick Place Convention Center, Room A

Poster number: 134

Speaker: Ekaterina Postovalova, PhD, BostonGene

This presentation demonstrates the ability of new advanced imaging technologies from the BostonGene pipeline to detect tertiary lymphoid structures (TLS) in lung cancer.

Summary of the online publication:

Abstract number: e20624

Title: Longitudinal molecular analysis of tumor exome and transcriptome to assess clonal evolution and identify novel therapeutic targets in thymoma

This abstract highlights the importance of longitudinal comprehensive molecular analysis using genomic and transcriptomic sequencing to improve understanding of rare thymic epithelial tumors.

Research conducted with Massachusetts General Hospital

For more information, please visit ASCO Annual Meeting 2022 website. Abstracts will be published online in the Journal of Clinical Oncology supplement for the proceedings of the ASCO annual meeting.

About BostonGene Corporation

BostonGene’s mission is to propel the transition of healthcare to personalized medicine by using our AI-based molecular and immune profiling to improve the standard of care, accelerate research and improve the economy. BostonGene Tumor ProfileMT Trials reveal key drivers of each tumor, including properties of the immune microenvironment, actionable mutations, biomarkers of response to various therapies, and recommended therapies. With these comprehensive scans, BostonGene Tumor PortraitMT The tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.

Share.

Comments are closed.